Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer

Digestion

Volumn 87, Issue 1, 2013, Pages 59-64

  Yoshida, Motoki ^a   Goto, Masahiro ^a   Kii, Takayuki ^a   Nishitani, Hitoshi ^a   Kawabe, Shinichiro ^a   Kuwakado, Shin ^a   Asaishi, Ken ^a   Miyamoto, Takahiro ^a   Higuchi, Kazuhide ^a  

^a OSAKA MEDICAL COLLEGE HOSPITAL   (Japan)

Author keywords

Bevacizumab; Colorectal cancer; First line chemotherapy; Fluoropyrimidine; Frail patients; S 1

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN;

AGED; ANEMIA; BOLUS INJECTION; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONFERENCE PAPER; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FATIGUE; FEMALE; FRAIL ELDERLY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; PERITONEUM METASTASIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RETROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT FAILURE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; FRAIL ELDERLY; HUMANS; LEUCOVORIN; MALE; NEOPLASM METASTASIS; OXONIC ACID; RETROSPECTIVE STUDIES; TEGAFUR; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84873814276     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000343943     Document Type: Conference Paper

References (20)

1. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-2019
2. Cutsem EV, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417
3. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010; 28: 4697-4705
4. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ, et al: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 2007; 370: 143-152
5. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ: Sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomized controlled trial. Lancet 2007; 370: 135-142
6. Ducreux M, Malka D, Mendiboure J, Etienne PL, Texereau P, Auby D, Rougier P, Gasmi M, Castaing M, Abbas M, Michel P, Gargot D, Azzedine A, Lombard-Bohas C, Geoffroy P, Denis B, Pignon JP, Bedenne L, Bouché O, Fédération Francophone de Cancérologie Digestive (FFCD) 2000-05 Collaborative Group: Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): An openlabel, randomised, phase 3 trial. Lancet Oncol 2011; 12: 1032-1044
7. Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B, Ducreux M, Azoulay D, Bismuth H, Castaing D: Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009; 27: 1829-1835
8. Cutsem EV, Nordlinger B, Cervantes A, ESMO Guidelines Working Group: Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol 2010; 21(suppl 5):v93-v97
9. Figer A, Perez-Staub N, Carola E, Tournigand C, Lledo G, Flesch M, Barcelo R, Cervantes A, André T, Colin P, Louvet C, de Gramont A: FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: An exploratory cohort of the OPTIMOX1 study. Cancer 2007; 110: 2666-2671
10. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez- Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006; 24: 394-400
11. Jackson NA, Barrueco J, Soufi-Mahjoubi R, Marshall J, Mitchell E, Zhang X, Meyerhardt J: Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer. Cancer 2009; 115: 2617-2629
12. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 50: 335-2342
13. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S: Combined analysis of efficacy: The addition of Bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-3712
14. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-2019
15. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-3705
16. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ: Capecitabine, bevacizumab and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX study. J Clin Oncol 2010; 28: 3191-3198
17. Takahari D, Takiuchi H, Muro K, Tsuji A, Hamamoto Y, Yoshino T, Yoshida K, Shirao K, Miyata Y, Ohtsu A: Phase II trial of combination therapy with bevacizumab and S-1 in elderly patients with unresectable or recurrent colorectal cancer (BASIC). Eur J Cancer Abstract Book 2011(abstr 6121):428- 429
18. Feliu J, Safont MJ, Salud A, Losa F, García- Girón C, Bosch C, Escudero P, López R, Madronal C, Bolanos M, Gil M, Llombart A, Castro-Carpeno J, González-Barón M: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer 2010; 102: 1468-1473
19. Yancik R, Wesley MN, Ries LA, Havlik RJ, Long S, Edwards BK, Yates JW: Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: population-based study. Cancer 1998; 82: 2123-2134
20. Sastre J, Grávalos C, Rivera F, Massuti B, Valladares- Ayerbes M, Marcuello E, Manzano JL, Benavides M, Hidalgo M, Díaz-Rubio E, Aranda E: First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: Clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD group study. Oncologist 2012; 17: 339-345